

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of treatment comprising:

administering to a subject a pharmaceutical preparation having ~~The use of~~ a therapeutic protein S-nitroso albumin having SH-groups which are nitrosated, and ~~of~~ a compound containing thiol groups and having an average molecular weight of at most 10,000 for treating ~~for the manufacture of a pharmaceutically combined preparation for the treatment of ischaemia and reperfusion injury, shock, in particular traumatic, hypovolaemic and haemorrhagic shock, respectively, or neurogenic shock, thrombotic conditions, respiratory tract diseases, erectile dysfunctions in men and hypertension.~~

2. (Currently Amended) The method use according to claim 1, wherein at least 90% of the ~~present~~ SH-groups of the therapeutic protein are nitrosated.

3. (Cancelled)

4. (Currently Amended) The method use according to claim 1, wherein the compound containing thiol groups is at least one of reduced glutathione, L-cysteine, N-acetyl cysteine, L-cysteinyl glycine, γ -glutamyl cysteine, penicillamine, penicillamide, N-acetyl penicillamine, N-acetyl penicillamide, homocysteine, captopril, dihydrolipoic acid and the oxidized form thereof, which, after administration, is reduced in vivo, ~~is/are contained as the compound containing thiol groups.~~

5. (Currently Amended) The method use according to claim 1 3, wherein ~~S-nitroso albumin is contained as the therapeutic protein having nitrosated SH groups, and reduced glutathione is contained as the compound containing thiol groups.~~

6. (Currently Amended) The method use according to claim 4, wherein a compound occurring in human blood and tissue, selected from ~~in particular at least one of~~ reduced

glutathione, L-cysteine, L-cysteinyl glycine, γ -glutamyl cysteine ~~or and~~ dihydrolipoic acid, is contained as the compound containing thiol groups.

7. (Currently Amended) The method use according to claim 1, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.

8. (Currently Amended) The method use according to claim 2, wherein at least one of S-nitroso albumin, S-nitroso orosomucoid, S-nitroso plasminogen activator, S-nitroso fibrinogen, S-nitroso Lys-plasminogen and S-nitroso haemoglobin is contained as the therapeutic protein having nitrosated SH-groups.

9. (Currently Amended) The method use according to claim 2, wherein the compound containing thiol groups is at least one of reduced glutathione, L-cysteine, N-acetyl cysteine, L-cysteinyl glycine, γ -glutamyl cysteine, penicillamine, penicillamide, N-acetyl penicillamine, N-acetyl penicillamide, homocysteine, captopril, dihydrolipoic acid and the oxidized form thereof, which, after administration, is reduced in vivo, ~~is/are contained as the compound containing thiol groups.~~

10. (Currently Amended) The method use according to claim 4, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

11. (Currently Amended) The method use according to claim 8, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

12. (Currently Amended) The method use according to claim 9, wherein S-nitroso albumin is contained as the therapeutic protein having nitrosated SH-groups, and reduced glutathione is contained as the compound containing thiol groups.

13. (Currently Amended) The method ~~use~~ according to claim 9, wherein a compound occurring in human blood and tissue, in particular at least one of reduced glutathione, L-cysteine, L-cysteinyl glycine, γ -glutamyl cysteine and dihydrolipoic acid, is contained as the compound containing thiol groups.

14. (Currently Amended) The method ~~use~~ according to claim 2, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.

15. (Currently Amended) The method ~~use~~ according to claim 3, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.

16. (Currently Amended) The method ~~use~~ according to claim 4, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.

17. (Currently Amended) The method ~~use~~ according to claim 5, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.

18. (Currently Amended) The method ~~use~~ according to claim 6, wherein a therapeutic protein obtained by nitrosation is contained in the pharmaceutical preparation, which the degree of nitrosation is made up of S-nitrosation by at least 90% and of N-nitrosation, O-nitrosation, or C-nitrosation by at most 10%.